Search

Your search keyword '"anaplastic lymphoma kinase (ALK)"' showing total 514 results

Search Constraints

Start Over You searched for: Descriptor "anaplastic lymphoma kinase (ALK)" Remove constraint Descriptor: "anaplastic lymphoma kinase (ALK)"
514 results on '"anaplastic lymphoma kinase (ALK)"'

Search Results

1. Inflammatory myofibroblastic tumor from molecular diagnostics to current treatment.

2. A New Approach of Detecting ALK Fusion Oncogenes by RNA Sequencing Exon Coverage Analysis.

3. Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum.

4. Overexpression of Fibroblast Growth Factor 8 Is a Predictor of Impaired Survival in Esophageal Squamous Cell Carcinoma and Correlates with ALK/EML4 Alteration.

5. Bilateral breast metastases from anaplastic lymphoma kinase-positive lung cancer in a male: a case report

6. Bilateral breast metastases from anaplastic lymphoma kinase-positive lung cancer in a male: a case report.

7. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK‐positive advanced non–small cell lung cancer.

9. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.

10. EGFR mutations in lung cancer: Implications for personalized therapy.

11. Anaplastic large cell lymphoma presenting as a mass in the uterine cervix: a case report.

12. Anaplastic Lymphoma Kinase (ALK) in Posterior Cranial Fossa Tumors: A Scoping Review of Diagnostic, Prognostic, and Therapeutic Perspectives.

13. Anaplastic lymphoma kinase-positive inflammatory myofibroblastic tumor of the breast: a case report and review of the literature

14. Traumatic tumor hemorrhage of inflammatory myofibroblastic tumor of the lung

15. A three-year review of lung cancer patient characteristics in a tertiary hospital.

16. Anaplastic lymphoma kinase-positive inflammatory myofibroblastic tumor of the breast: a case report and review of the literature.

17. Inflammatory Myofibroblastic Tumor (IMT) of the Trachea Excised by Transtracheal Surgery: Case Report.

18. How to select the best upfront therapy for metastatic disease? Focus on ALK-rearranged non-small cell lung cancer (NSCLC).

19. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.

20. Photosensitivity associated with anaplastic lymphoma kinase inhibitors: A review of postmarketing cases reported to FDA and published in the literature.

21. Efficacy and safety of first‐line treatments for patients with advanced anaplastic lymphoma kinase mutated, non–small cell cancer: A systematic review and network meta‐analysis.

22. CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.

23. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models

24. Modern treatment of ALK-positive non-small cell lung cancer

25. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt

26. Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK -Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501).

27. Treatment of metastatic ALK-positive non-small cell lung cancer: real-world outcomes in a single center study.

28. Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma

29. The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

30. Superficial ALK-rearranged myxoid spindle cell neoplasms: Clinicopathologic and molecular analysis of two cases and a review of the literature.

31. ALK-Positive Histiocytosis: A Case Report and Literature Review

33. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.

34. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.

35. Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced nonsmall cell lung cancer

36. Spontaneous pneumothorax caused by an inflammatory myofibroblastic tumor-like lesion in a 14-year-old girl: a case report

37. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lymphoepithelioma‐like carcinoma

38. What do we know about the role of neoadjuvant targeted therapy in early-stage EGFR -mutant and ALK -fused non-small cell lung cancer?-a narrative review of the current literature.

39. Efficacy of ALK inhibitors in Asian patients with ALK inhibitor-naïve advanced ALK -positive non-small cell lung cancer: a systematic review and network meta-analysis.

40. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.

41. Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma.

42. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer

43. The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer.

44. ALK-Positive Histiocytosis: A Case Report and Literature Review.

45. 18F-FDG PET/CT imaging findings in anaplastic large cell lymphoma, a rare subtype of lymphoma

46. Small Molecule Inhibitors of ALK

47. A rare case of urachal inflammatory myofibroblastic tumor

48. Pathological complete response to neoadjuvant lorlatinib in a patient with stage IIIA ALK -positive non-small cell lung cancer: a case report.

49. Executive summary of the American Radium Society appropriate use criteria for brain metastases in epidermal growth factor receptor mutated-mutated and ALK-fusion non-small cell lung cancer.

50. Analysis of the resistance profile of real-world alectinib first-line therapy in patients with ALK rearrangement-positive advanced non-small cell lung cancer using organoid technology in one case of lung cancer.

Catalog

Books, media, physical & digital resources